Lunai Bioworks Inc.
NCM: LNAILive Quote
📈 ZcoreAI Score
Our AI model analyzes Lunai Bioworks Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get LNAI Z-Score →About Lunai Bioworks Inc.
Healthcare
Biotechnology
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
📊 Fundamental Analysis
Lunai Bioworks Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -366.4%, which indicates that capital utilization is currently under pressure.
At a current price of $0.37, LNAI currently trades near the bottom of its 52-week range (4%), indicating potential value or weakness (Range: $0.15 - $5.50).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$8.97M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
0.49
52W High
$5.50
52W Low
$0.15
Avg Volume
18.98M
Day High
Day Low